


CLAIMS

1- Association of compound (A) of formula (I), optionally in the form of an optical isomer or one of its pharmaceutically acceptable salts, and aspirin, or one of its pharmaceutically acceptable salts :



5

2- Association according to claim 1, characterised in that compound (A) is in (R) configuration optical isomer form.

3- Association according to either claim 1 or claim 2, characterised in that compound (A) is in the form of a sodium salt.

10

4- Pharmaceutical composition comprising as active ingredients an association of compound (A), optionally in the form of an optical isomer or one of its pharmaceutically acceptable salts, and aspirin, or one of its pharmaceutically acceptable salts, in combination with one or more pharmaceutically acceptable, inert excipients or carriers.

15

5- Pharmaceutical composition according to claim 4, characterised in that compound (A) is in (R) configuration optical isomer form.

6- Pharmaceutical composition according to either claim 4 or claim 5, characterised in that compound (A) is in sodium salt form.

7- Pharmaceutical composition according to any one of claims 4 to 6, characterised in that the amounts of active ingredients are in the respective ranges of from 1 to 300 mg for compound (A) and from 10 to 1000 mg for aspirin.

5 8- Pharmaceutical composition according to any one of claims 4 to 7, for use in the treatment of atherothrombotic illnesses involving the activation of TP receptors and/or the formation of metabolites and also in the treatment of consequences of those illnesses.